Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad257 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Çağlar Ünal und 59 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey. Hauptthemen laut MEDLINE: Neuroendocrine Tumors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).
Methods
We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.
Results
The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment. Conclusions and Relevance The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey.
- Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey.
- Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey.
- Division of Medical Oncology, Department of Internal Medicine, Uludağ University Hospital, Bursa, Turkey.
- Division of Medical Oncology, Department of Internal Medicine, Dicle University Hospital, Diyarbakır, Turkey.
- Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa University Hospital, İstanbul, Turkey.
ORCID-Profile: Çağlar Ünal
Zitieren
APA
Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., Yalçın, Ş., Çoban, E., Evrensel, T., Kalkan, Z., Oruç, Z., Derin, S., Turna, Z. H., Bayram, D., Köş, F. T., Şendur, M. A. N., Sever, N., Ercelep, Ö., Seyyar, M., …, & Aydınalp, Y. (2023). Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. The Oncologist. https://doi.org/10.1093/oncolo/oyad257
Vancouver
Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, et al. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. The Oncologist. 2023. doi:10.1093/oncolo/oyad257
BibTeX
@article{nal2023,
author = {Ünal, Çağlar and Azizy, Abdulmunir and Karabulut, Senem and Taştekin, Didem and Akyıldız, Arif and Yaşar, Serkan and Yalçın, Şuayib and Çoban, Eyüp and Evrensel, Türkkan and Kalkan, Ziya and Oruç, Zeynep and Derin, Sümeyra and Turna, Zeynep Hande and Bayram, Doğan and Köş, Fahriye Tuğba and Şendur, Mehmet Ali Nihat and Sever, Nadiye and Ercelep, Özlem and Seyyar, Mustafa and Kefeli, Umut and Uygun, Kazım and Özçelik, Melike and Ön, Sercan and Şanlı, Ulus Ali and Canaslan, Kübra and Ünek, İlkay Tuba and Yücel, Kadriye Bir and Özdemir, Nuriye and Yazıcı, Ozan and Güzel, Halil Göksel and Salim, Derya Kıvrak and Göksu, Sema Sezgin and Tatlı, Ali Murat and Ordu, Çetin and Selvi, Oğuzhan and Sakin, Abdullah and Büyükbayram, Mehmet Emin and Dursun, Bengü and Ürün, Yüksel and Arak, Hacı and Ağdaş, Gözde and Uğraklı, Muzaffer and Hendem, Engin and Eryılmaz, Melek Karakurt and Bilgin, Burak and Topçu, Atakan and Şimşek, Melih and Büyükşimşek, Mahmut and Akay, Büşra and Erdal, Gülçin Şahingöz and Karataş, Fatih and Alan, Özkan and Çağlayan, Melek and Kahvecioğlu, Fatma Akdağ and Demirci, Ayşe and Paksoy, Nail and Çetin, Bülent and Gümüş, Mahmut and Ak, Naziye and Aydınalp, Yasemin},
title = {Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad257}
}
EUVIMED